Shop ASCO Immune-related Adverse Events ... Checkpoint Inhibitor Therapy

Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy

Published: November 2021
$21.95
Print Copy Information:
  • 72 pages
  • Spiral Bound
  • 80# Aqueous Coating
  • 4.25" x 7.25"
  • Ships in 5 – 10 business days
Add to Cart
What's Inside
Bulk and Institutional Ordering
About the Authors
Additional Information
  • Key Points
  • Key Recommendations
  • Tables
    • Immunosuppressive Agents
    • Commonly Conducted Testing at Baseline Prior to ICPi Therapy
    • Commonly Conducted Testing During irAE Management With Steroids
    • Cutaneous Toxicities
    • Gastointestinal Toxicities
    • Lung Toxicities
    • Endocrine Toxicities
    • Musculoskeletal Toxicities
    • Renal Toxicities
    • Nervous System Toxicities
    • Hematologic Toxicities
    • Cardiovascular Toxicities
    • Ocular Toxicities
    • Systemic Toxicities
    • Prevention and Management of Adverse Events Related to Steroid Use
  • For purchases under 100 in quantity, we suggest placing the order directly through the website.
  • We offer group/institutional licenses for multi-user accounts (discount amount varies depending on the number of users).
  • We are proud to offer special discounts to medical schools, training programs, students and more.
  • We offer bulk purchase discounts based on number of copies and number of titles.

Contact Us for more details

Founded in 1964, the American Society of Clinical Oncology is the world's leading professional organization for physicians and oncology professionals caring for people with cancer.

Description

This pocket guide is derived from recommendations in the American Society of Clinical Oncology Guideline. This resource is a practice tool based on ASCO® practice guidelines and is not intended to substitute for the independent professional judgment of the treating physician. Practice guidelines do not account for individual variation among patients. This pocket guide does not purport to suggest any particular course of medical treatment. Use of the practice guidelines and this resource are voluntary. The practice guidelines and additional information are available at www.asco.org/supportive-care-guidelines. Copyright © 2021 by American Society of Clinical Oncology. All rights reserved.

You can also find this product included in this bundle!

ASCO Guidelines Bundle

American Society of Clinical Oncology
Last Updated: Oct 11, 2023
$ 742.95 Print Included Guidelines:
  • Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer
  • Adjuvant Therapy for Stage III Colon Cancer
  • Advanced Gastroesophageal Cancer
  • Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer
  • Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer – Brain Metastases
  • Antiemetics
  • Antimicrobial Prophylaxis for Adult Patients With Cancer-Related Immunosuppression
  • Anxiety and Depression in Adult Survivors of Cancer
  • Appropriate Systemic Therapy Dosing for Obese Adult Patients with Cancer
  • Axilla Management in Early-Stage Breast Cancer
  • Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer
  • Biomarkers for Systemic Therapy in Metastatic Breast Cancer
  • Bone-Modifying Agents in Metastatic Breast Cancer
  • Bone-Modifying Agents in Multiple Myeloma
  • Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents
  • Cardiac Dysfunction - Prevention and Monitoring in Cancer Survivors
  • Cervical Cancer Prevention
  • Chemotherapy in Combination With Radiotherapy for Definitive-Intent Treatment of Stage II-IVA Nasopharyngeal Carcinoma
  • Chemotherapy-Naïve Castration-Resistant Prostate Cancer
  • Chronic Pain in Survivors of Adult Cancers
  • Clear Cell Renal Cell Carcinoma
  • Colorectal Cancer Biomarkers
  • Colorectal Cancer Early Detection
  • Diagnosis and Management of Squamous Cell Carcinoma of Unknown Primary in the Head and Neck
  • Diffuse Astrocytic and Oligodendroglial Tumors in Adults
  • Early-Stage Breast Cancer
  • Estrogen and Progesterone Receptor Testing in Breast Cancer
  • Exercise, Diet, and Weight Management During Cancer Treatment
  • Fertility Preservation
  • Germline and Somatic Tumor Testing in Epithelial Ovarian Cancer
  • Hepatitis B Virus Screening and Management for Patients with Cancer Prior to Therapy
  • HER2 Testing in Breast Cancer
  • Hormone Receptor–Positive Breast Cancer Adjuvant Endocrine Therapy
  • HR-Positive, HER2-Negative Metastatic Breast Cancer
  • Immune-related Adverse Events from Immune Checkpoint Inhibitor Therapy
  • Immune-related Adverse Events — CAR T-Cell Therapy
  • Initial Management of Noncastrate Advanced, Recurrent, or Metastatic Prostate Cancer
  • Integrative Medicine for Pain Management in Oncology
  • Integrative Oncology Care of Symptoms of Anxiety and Depression in Adult Patients with Cancer
  • Invasive Cervical Cancer
  • Laryngeal Cancer
  • Late-Stage Colorectal Cancer
  • Lung Cancer Surveillance After Definitive Curative-Intent Therapy
  • Malignant Pleural Mesothelioma
  • Management of Cancer Cachexia
  • Management of Dyspnea in Advanced Cancer
  • Management of Hereditary Breast Cancer
  • Management of Male Breast Cancer
  • Management of Osteoporosis
  • Management of Salivary Gland Malignancy
  • Management of the Neck in Squamous Cell Carcinoma of the Oral Cavity and Oropharynx
  • Medication-Related Osteonecrosis of the Jaw
  • Metastatic Colorectal Cancer
  • Metastatic HER2-Negative Breast Cancer – Chemo- and Targeted Therapy
  • Metastatic Pancreatic Cancer
  • Metastatic Well-differentiated Gastroenteropancreatic Neuroendocrine Tumors
  • Molecular Biomarkers in Localized Prostate Cancer
  • Multiple Myeloma
  • Neoadjuvant Chemotherapy for Newly Diagnosed, Advanced Ovarian Cancer
  • Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer
  • Non-Small Cell Lung Cancer — Adjuvant Therapy for Completely Resected Stages I-IIIA
  • Optimum Imaging Strategies for Advanced Prostate Cancer
  • Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy
  • Ovarian Masses and Treatment of Epithelial Ovarian Cancer
  • Palliative Care in the Global Setting
  • Pancreatic Cancer - Evaluating Susceptibility
  • PARP Inhibitors in the Management of Ovarian Cancer
  • Penile Cancer
  • Platelet Transfusion
  • Potentially Curable Pancreatic Adenocarcinoma
  • Prevention And Management Of Chemotherapy-Induced Peripheral Neuropathy In Survivors Of Adult Cancers
  • Recurrent and Metastatic Head and Neck Cancers
  • Salivary Gland Hypofunction and/or Xerostomia
  • Secondary Prevention of Cervical Cancer
  • Selection of Optimal Adjuvant Chemotherapy and Targeted Therapy for Early Breast Cancer
  • Small Renal Masses
  • Somatic Genomic Testing for Metastatic or Advanced Cancer
  • Stage II Colon Cancer Adjuvant Therapy
  • Stage III Non-Small Cell Lung Cancer
  • Stage IV Non-Small Cell Lung Cancer without Driver Alterations
  • Systemic Therapy for Advanced Hepatocellular Carcinoma
  • Systemic Therapy for Melanoma
  • Systemic Therapy for Small Cell Lung Cancer
  • Therapy for Stage IV Non-Small-Cell Lung Cancer With Driver Alterations
  • Treatment for Brain Metastases
  • Treatment of Early-Stage Colorectal Cancer
  • Treatment of Locally Advanced Esophageal Carcinoma
  • Treatment of Metastatic Carcinoma and Myeloma of the Femur
  • Use of Endocrine Therapy for Breast Cancer Risk Reduction
  • Use of Opioids for Cancer Pain
  • Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer
  • Vulnerabilities in Older Patients Receiving Systemic Cancer Therapy
  • White Blood Cell Growth Factors
Add to Cart
Need help?